Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine.

British journal of pharmacology - 1 Mar 2005

Kennard Louise E, Chumbley Justin R, Ranatunga Kishani M, Armstrong Stephanie J, Veale Emma L, Mathie Alistair

Abstract excerpt

1. Block of the human two-pore domain potassium (2-PK) channel TREK-1 by fluoxetine (Prozac) and its active metabolite, norfluoxetine, was investigated using whole-cell patch-clamp recording of currents through recombinant channels in tsA 201 cells. 2. Fluoxetine produced a concentration-dependent inhibition of TREK-1 current that was reversible on wash. The IC50 for block was 19 microM. Block by fluoxetine was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dose-Response Relationship, Drug
Share to Fluoxetine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Patch-Clamp Techniques

Share to Potassium Channel Blockers

Share to Potassium Channels, Tandem Pore Domain

Share to Selective Serotonin Reuptake Inhibitors

Share to Transfection

Source

Open in PubMed Open full text

Identifiers

PMID: 15685212
DOI: 10.1038/sj.bjp.0706068
PMCID: PMC1576064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine.PMID 15685212Read ↗

Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.Semantic proximity Read ↗

Influence of the N terminus on the biophysical properties and pharmacology of TREK1 potassium channels.Semantic proximity Read ↗

Inhibition of human TREK-1 channels by caffeine and theophylline.Semantic proximity Read ↗

Dominant negative effects of a non-conducting TREK1 splice variant expressed in brain.Semantic proximity Read ↗

Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype.Semantic proximity Read ↗

Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.Semantic proximity Read ↗

A Human TREK-1/HEK Cell Line: A Highly Efficient Screening Tool for Drug Development in Neurological DiseasesSemantic proximity Read ↗

Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone.Semantic proximity Read ↗

Tricyclic antidepressants inhibit homomeric Cys-loop receptors by acting at different conformational states.Semantic proximity Read ↗

Effects of Remimazolam and Propofol on Ca2+ Regulation by Ryanodine Receptor 1 with Malignant Hyperthermia Mutation.Semantic proximity Read ↗

Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics.Semantic proximity Read ↗

Local-anesthetic like inhibition of the cardiac sodium channel Nav1.5 α-subunit by 5-HT3 receptor antagonists.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.